Evidence map›Paper›PMID 35198544›Full record

ReviewFrontiers in bioengineering and biotechnology2022

Development of Metal-Organic Framework-Based Dual Antibody Nanoparticles for the Highly Specific Capture and Gradual Release of Circulating Tumor Cells.

Mingchao Hu, Cheng Li, Zhili Wang, Pi Ding, Renjun Pei, Qiang Wang, Hua Xu, Chungen Xing

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Mingchao HuDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Cheng LiSchool of Nano-Tech and Nano-Bionics, University of Science and Technology of China, Hefei, China.
Zhili WangSchool of Nano-Tech and Nano-Bionics, University of Science and Technology of China, Hefei, China.
Pi DingSchool of Nano-Tech and Nano-Bionics, University of Science and Technology of China, Hefei, China.
Renjun PeiSchool of Nano-Tech and Nano-Bionics, University of Science and Technology of China, Hefei, China.
Qiang WangDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Hua XuDepartment of General Surgery, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou, China.
Chungen XingDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
University of Science and Technology of China · CNNanjing Medical University · CNSecond Affiliated Hospital of Soochow University · CNSoochow University · CNSoutheast University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulating tumor cells (CTCs) have been well-established as promising biomarkers that can be leveraged to gauge the prognosis of patients with cancers and to guide patient treatment efforts. Although the scarcity of CTCs within peripheral circulation and the associated phenotypic changes that they exhibit owing to the epithelial-mesenchymal transition (EMT) process make the reliable isolation of these cells very challenging. Recently, several studies have discussed platforms capable of mediating the efficient and sensitive isolation of CTCs, but these approaches are nonetheless subject to certain limitations that preclude their clinical application. For example, these platforms are poorly-suited to minimizing damage in the context of cellular capture and release or the

Indexed as

cell releasecirculating tumor cellsisolationlayer-by-layer assembly methodmetal organic frameworks

Identifiers

PMID35198544
PMCPMC8859420
OpenAlexW4210595555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.